GRCL - Gracell Biotechnologies - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

62.88M

Cash

1.192B

Avg Qtr Burn

-139.9M

Short % of Float

0.65%

Insider Ownership

23.41%

Institutional Own.

52.90%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GC007g Details B-cell acute lymphoblastic leukemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GC012F Details Multiple myeloma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GC012F Details Autoimmune disease, Systemic lupus erythematosus	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.